Ulrichts
Dieter Ulrichts, Brugge BE
Patent application number | Description | Published |
---|---|---|
20150031917 | PROCESS FOR THE PRODUCTION OF CHOLINE HYDROXIDE - A continuous process for the production of choline hydroxide includes reacting ethylene oxide, trimethylamine, and water in a reaction zone to form a reaction mixture and extracting heat from the reaction mixture. Subsequently, phase separation of the s reaction mixture is induced to obtain a choline hydroxide phase and an organic liquid phase comprising trimethylamine. A choline hydroxide solution (e.g., at a concentration of about 40% to 50% by weight, based on total weight of the choline hydroxide solution) is obtained from the choline hydroxide phase. | 01-29-2015 |
Hans Ulrichts, Kortrijk BE
Patent application number | Description | Published |
---|---|---|
20110158996 | VON WILLEBRAND FACTOR SPECIFIC BINDERS AND METHODS OF USE THEREFOR - The invention provides new uses for specific binders to the Al domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided. | 06-30-2011 |
20120321640 | VON WILLEBRAND FACTOR SPECIFIC BINDING AGENTS AND USES THEREOF - The invention provides new uses, compositions and methods of administration for specific binding agents to von Wiliebrand Factor (vWF) in patients with thromboembolic disorders and in particular new combined uses with thrombolytic agents such as tissue plasminogen activator in patients with thromboembolic disorders such as e.g. ischemic stroke. Furthermore, a new group of vWF binding agents and an improved Middle Cerebral Artery Thrombosis Model in guinea pigs to study the effects of stroke such as ischemia (oxygen and glucose depriviation) and hemorrhage (bleeding), in particular hemorrhage, are provided. | 12-20-2012 |
20140044710 | VON WILLEBRAND FACTOR SPECIFIC BINDERS AND METHODS OF USE THEREFOR - The invention provides new uses for specific binders to the A1 domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided. | 02-13-2014 |
Peter Ulrichts, Destelbergen BE
Patent application number | Description | Published |
---|---|---|
20140147450 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 05-29-2014 |
20140235843 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 08-21-2014 |
Peter Ulrichts, Breda NL
Patent application number | Description | Published |
---|---|---|
20140286976 | CHIMERIC HUMAN-LLAMA ANTIGENS AND METHODS OF USE - Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen. | 09-25-2014 |